The Critical Need for the End to End Data Flows for Regenerative Therapies

Thu, Nov 08, 2018 | By Tom Heinzen, VP, Corporate Development & Investor Relations, Cryoport

The global commercial approval of the first CAR-T therapies (Kymriah® and Yescarta®) has intensified the need for the clear and uninterrupted flow of data from before the patient is ever treated...

Beyond Logistics – What’s Needed for Successful Support of Clinical Trials and Commercialization in Regenerative Medicine?

Wed, Oct 31, 2018 | By Sue Blecman, Senior Director, Business Development, Cryoport

The tedious process of vendor selection for Clinical Trials, Commercialization Planning and Launch in Regenerative Medicine can be daunting, let alone having to think about the Support necessary...

The Emergence of Chain of Compliance™

Mon, Sep 24, 2018 | By Allie Gerber, Marketing Manager, Cryoport

In December 2016 the US Congress enacted the 21st Century Cures Act, which required the FDA to facilitate an efficient development program for, and expedite the review of, new medicines meeting...

Compliance Considerations Driving Temperature-Controlled Logistics

Tue, Sep 04, 2018 | By Ryan Carpentier, Sr. Director, Business Development, Cryoport

When considering your temperature-controlled logistics needs, it is important to think about the compliance consideration steps in the drug development and delivery process being more than just...

Cryoport Practices Quality by Design (QbD) Approaches When Developing New Products and Processes

Thu, Apr 13, 2017 | By Allie Gerber, Marketing Manager, Cryoport

Cryoport is the industry’s most trusted provider of cold chain logistics solutions for temperature-sensitive life sciences materials, serving biopharmaceutical, IVF and surrogacy and animal health...